“We assume that these people are friends and family of people who are at risk of an opioid overdose and want to have a naloxone kit on hand in case they are able to intervene to help save that person’s life,” said Dr. Tara Gomes
Patients with overactive bladder who were dispensed mirabegron did not have an increased risk for cardiovascular events compared with other treatments, according to a study published in JAMA Internal Medicine.
Meanwhile, a new report from the Ontario Drug Policy Research Network looked at 1,337 opioid-related deaths in the province from July 2017 to June 2018.
Of the 147,303 publicly funded naloxone kits distributed across the province between July 2017 and June 2018, 8,657 were handed out in the Middlesex-London Health Unit coverage area — a rate of 1,813 per 100,000 people — a new study by the ODPRN says.
Using Ontario’s health record databases, Drs. Gomes and Antoniou, scientists at the Li Ka Shing Knowledge Institute and ICES, and members of their team will be studying how successful the program has been in providing naloxone to eligible individuals.